Due to regulatory restrictions regarding the distribution
of financial research, this report is restricted to a specific
region or investor type. Get access to exclusive reports
by answering the questions below.
This combination of email and password didn't match our records. Your account might not be activated. If so, please click on the link we sent you via email. You can also request a password reset or a new activation email using the links below.
Your daily roundup of commodity news and ING views
No strong clues from the Friday session in Europe and the US will leave Asia looking for direction this Monday, ahead of global pointers such as this week's Fed meeting
The average covenant quality score for Asian high-yield bonds in the fourth quarter of 2020 was 3.63 (weak).
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
SHANGHAI, China, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that U.S. Food and Drug Administration (FDA) has granted toripalimab Fast Track designation for the first-line treatment of mucosal melanoma. Meanwhile, the FDA has also approved the Investigational New Drug (IND) application for a global Phase III trial of Toripalimab in combination wit...
First US Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
MELBOURNE, Australia and INDIANAPOLIS, Jan. 24, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that the first patients have been dosed in the Phase III ZIRCON1 clinical trial of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in the United States. The objective of the ZIRCON trial is to evaluate the sensitivity and specificity of PET/CT imaging with TLX250-CDx to non-invasively detect clear cell renal cell carcinoma (ccR...
Sixth Street has greater access to capital than the current ownership, making it easier for Talcott to grow its solutions and analytics business.
While no policy changes are likely we will get an update from Jerome Powell on how the Fed sees the outlook for the economy in the wake of new fiscal stimulus and the vaccine roll-out. A more positive assessment could bring forward expectations of QE tapering and eventual rate hikes
Published Monday and Thursday mornings, Moody’s Credit Outlook provides you with the credit implications of current events.
Strong Q4e but with less outstanding margins than in Q3 Forecasts adjusted for temporarily lower IPR revenues No new guidance but we expect update on IPR; BUY
Q4’20 was much better than expected, across the board We expect the high premium growth to continue into 2021 Downgrade to HOLD (Buy); TP up to DKK 310 (300)
Expect ’20 to end within the solid organic guidance range ’21 outlook to reflect caution, but also solid organic growth LT preferred BUY reiterated, TP up to DKK 512 (500)
DBRS, Inc. (DBRS Morningstar) confirmed the Commonwealth of Australia’s Long-Term Foreign and Local Currency – Issuer Ratings at AAA. At the same time, DBRS Morningstar confirmed the Commonwealth of Australia’s Short-Term Foreign and Local Currency – Issuer Ratings at R-1 (high). The trend on all ratings is Stable.
Please refer to PDF document for more detail about our research: Commonwealth of Australia - Scorecard Indicators and Building Block Assessments
Please refer to PDF document for more detail about our research: DBRS Morningstar Confirms Australia at AAA, Stable Trend
We are above consensus on key products for Q4 and believe Lundbeck will reach its 2020 guidance. We believe focus will be on 2021 with the loss of exclusivity (LoE) for Northera and the weak USD putting pressure on the outlook, which is not well reflected in consensus, we believe. We remain positive on the long-term growth outlook and believe Vyepti will start to show its potential in 2021. We reiterate our BUY and DKK255 target price.
We forecast Q4 global Darzalex sales of USD1,186m, driven by Darzalex Faspro (c38% of global sales). We expect significantly higher operating costs in the 2021 guidance than consensus, which we believe could be a negative. We have raised our target price to DKK2,500 (2,451), but struggle to justify the recent share price rise, and have hence downgraded to SELL (HOLD).
DraftKings Launches Mobile Sports Betting in Virginia
Arrival of Top-Rated Digital Sportsbook in Old Dominion Marks Company’s Twelfth State Launch
BOSTON, Jan. 24, 2021 (GLOBE NEWSWIRE) -- DraftKings Inc. (Nasdaq: DKNG) today announced the launch of DraftKings Sportsbook in Virginia, marking the 12th state in which the top rated mobile and online sportsbook is available. Customers in Virginia will now be able to place bets on a number of markets across professional and collegiate sports using the DraftKings made-in-America digital sportsbook app. “Just in time for Super Bowl LV, we are t...
Rating Action: Moody's assigns B2 CFR to Foundation Building Materials, senior secured term loan rated B2, senior notes Caa1; outlook stable. Global Credit Research- 22 Jan 2021. New York, January 22, 2021-- Moody's Investors Service assigned a B2 Corporate Family Rating and B2-PD Probability of Default Rating to Foundation Building Materials, Inc..
Our credit view of RPI Intermediate Finance, reflecting its high margins and strong cash flow, offset by its revenue concentration in key products.
Almarai reported a weaker than expected set of Q4 20 results. Although net income increased +7.7% yoy (-46.0% qoq) to SAR336mn, it came lower than the NCBC and consensus estimates of SAR375mn and SAR381mn, respectively. The variance is due to lower gross margins along with higher financing and zakat expenses. Almarai gross margin stood at 32.3%, the lowest on record and compared to our estimates of 34.8%.
Revenues increased +3.1% yoy to SAR3.82bn in Q4 20, in-line with our estimates. The reve...
Save your current filters as a new Interest
Would you like to receive real-time email alerts when a new report is published under this interest?
These search results will show up under 'Saved searches' in the left panel
Would you like to receive real-time email when a new report matches this search?
Due to regulatory restrictions regarding the distribution of financial research, this
report is restricted to a specific region or investor type. Get access to exclusive reports
by answering the questions below.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.